Abstract:
Objective This study aims to investigate the effect of Kinglong capsules in malignant tumor patients with hypercoagulable state.
Methods A total of 106 malignant tumor patients with hypercoagulable state were divided into the observation (G1) and control groups (G2). In G1, 53 patients started taking the Kinglong capsules (1.0 g each time, 3 times a day) after their first chemotherapy cycle, until the beginning of next chemotherapy cycle. In G2, the other 53 patients took chemotherapy only. The value of PLT(platelet), Fib(Fibrinogen), PT(prothrombin time), APTT(activated partial thrombopoastin time), and D-D(D-dimer) for each patient was detected before the initial and the next cycle of chemotherapy. The value of PLT, Fib, PT, APTT, and D-D in the two groups was analyzed using statistical methods. The efficacy was evaluated after two cycles of chemotherapy; adverse reactions were evaluated after each cycle.
Result The time of PT and APTT was prolonged (P=0.021) significantly, and the value of PLT, Fib, and D-D decreased (P=0.043) significantly after treatment with Kinglong capsules. The short-term therapeutic efficacy was not statistically significant (P=0.073) between the two groups. Moreover, the Ⅲ–Ⅳ degree of neutropenia was significantly lower in the observation group than the control group (P=0.042).
Conclusion The results of chemotherapy combined with Kinglong capsules can prolong the PT and APTT time and reduce the value of PLT, Fib, and D-D significantly, thereby improving the hypercoagulable state in malignant tumor patients.